Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Hmu CRC LLC

Neither a doctor nor a teaching hospital

Research payments

$2,252,091

373 payments

Through program year 2025, Hmu CRC LLC is reported as receiving $2,252,091 in research payments, across 373 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $260,310 40
2024 Research $612,852 41
2023 Research $501,313 49
2022 Research $54,621 14
2021 Research $17,475 7
2020 Research $196,692 77
2019 Research $608,828 145

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $964,385 159 payments
  2. Pfizer Inc. $632,389 152 payments
  3. Veru Inc. $421,175 34 payments
  4. Sumitomo Pharma America, Inc. $82,843 15 payments
  5. Teleflex LLC $80,790 1 payment
  6. Palette Life Sciences, Inc. $66,153 9 payments
  7. Boston Scientific Corporation $4,356 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Efficacy and Safety Study of Enzalutamide Plus Leuprolide Enzalutamide Monotherapy and Placebo Plus Leuprolide in Men With Highrisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy $632,389 152 payments
  2. Veracity - Randomized, Active-Controlled, Phase 3 Study of Veru-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent $360,245 25 payments
  3. A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo $286,574 18 payments
  4. A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc $207,611 17 payments
  5. A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) $158,408 18 payments
  6. Barrigel Prostate Trial $80,790 1 payment
  7. A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) $75,186 22 payments
  8. Randomized Trial of Barrigel $66,153 9 payments
  9. Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (Replace-Cv) $49,583 8 payments
  10. A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer $39,220 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record